Merck scraps another late-stage Alzheimer's drug study

NEW YORK (Reuters) - Merck & Co Inc on Tuesday said it will end another late-stage trial of an Alzheimer’s drug because it was unlikely to work, adding to the pile-up of failures to find an effective treatment for the mind-wasting disease. The company was testing the drug, Verubecestat, in patients with very early, or prodromal, Alzheimer’s disease. It scrapped the study almost exactly one year...